Table 1.

Patient demographics and baseline characteristics among patients receiving ranibizumab for nAMD treatment in the health care settings of Australia and UK

	AUS cohort	UK cohort	p value
Patients	N = 570	N = 2755
Eyes	N = 647	N = 3187
Mean [SD] age in years	78.49 [6.76]	77.96 [8.14]	0.6573
Proportion of patients per age group at index date in %			0.0027
<65 years	3.40	6.46
65–69 years	9.58	6.78
70–74 years	12.67	12.52
75–79 years	19.17	21.65
80–84 years	36.01	32.44
≥85 years	19.17	20.14
Gender (patient) in %			0.0312
Female	57.82	63.67
Male	42.18	36.33
VA study eye (eye)			0.1979
N	647	3187
Mean [SD], letters	54.89 [18.82]	55.05 [15.59]
VA fellow eye (eye)			<0.0001
N	273	2883
Mean [SD], letters	65.19 [18.56]	59.65 [23.86]
VA functional groups (eye)
>70 letters	21.48	17.29
56–70 letters	31.84	33.51
35–55 letters	34.47	37.68
<35 letters	12.21	11.52

AUS Australia, N number of eyes, SD standard deviation, VA visual acuity